Clinical experience with lobeline as a smoking cessation agent

Medicinal Chemistry Research

Volumn 6, Issue 7-8, 1996, Pages 562-570

  Schneider, F Howard ^a   Olsson, Theodore A ^a  

^a DynaGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000025662     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Ejrup, B. Proposals for treatment of smokers with severe clinical symptoms brought about by their smoking habit. British Colombia Medical Journal 1960; 2, 441-454.
2. Farago, I. Ergebrisse der entwöhningskuren von 1125 rauchern:beitrag zum nikotinsuchtproblem. Schweizer Archiv für Neurologie Neurochirurgie und Psychiatrie 1968; 102, 167-189.
3. Kalyuzhny, V.V. The treatment of nicotinism with the aid of lobelin and its influence on vegetative and vascular reactions (in Russia). Journal of Neuropathological Psychiatry 1968; 68, 1864-1870.
4. Department of Health and Human Services, Food and Drug Administration. Smoking deterrant drug products for over-the-counter human use. June 1, 1993; 58(103) FR 31236.
5. Unpublished observation, DynaGen, Inc., Cambridge, MA.
6. 3H](-)-nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacology 1990; 29, 619-624.
7. Schneider, F.H.; Mione, P.J.; Raheman, F.S.; Phillips, B.M.; and Quiring, J.N. Reduction of tobacco withdrawal symptoms by sublingual lobeline sulfate. Submitted to American Journal of Health Behavior.
8. Glover, E.D.; Leischow, S.J.; Rennard, S.I.; Glover, P.N.; Daughton, D.; Quiring, J.N.; and Schneider, F.H. A multi-center phase 3 study of lobeline sulfate for smoking cessation. Submitted to Psychopharmacology.